the aid library

Filter

2814

Target product profile for a gambiense human African trypanosomiasis test to identify individuals to receive widened treatment

World Health Organization World Health Organization WHO (2022) C_WHO

The development of this target product profile (TPP) was led by the WHO Department of Control of Neglected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical ... more

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection - AIDSinfo

AIDSinfo (2019) C2

Downloaded from https://aidsinfo.nih.gov/guidelines on 10/19/2019 Developed by the HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV—A Working Group of the Office of AIDS Research Advisory Council (OARAC)

Adverse Effects of Crystalline Silica Exposure

American Thoracic Society (1996) CC2

This American Thoracic Society Statement was prepared by a Committee of the Scientific Assembly on Environmental and Occupational Health at the request of the American Lung Association Occupational Health Expert Advisory Group to emphasize the conti ... more

Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

Development of Health and Human Services USA; AIDSinfo Development of Health and Human Services USA; AIDSinfo (2020) C2

Developed by the HHS Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission— A Working Group of the Office of AIDS Research Advisory Council (OARAC) Accessed: 12.02.2020

Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine

World Health Organization WHO (2022) C_WHO

6 June 2022 These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included ... more

Declaração provisória sobre vacinação heteróloga contra a COVID-19

Organização Mundial da Saúde (OMS) (2021) CC

A Organização Mundial da Saúde (OMS), com apoio do Grupo Consultivo Estratégico de Especialistas em Imunização (Strategic Advisory Group of Experts on Immunization – SAGE) e do respectivo Grupo de Trabalho para Vacinas contra a COVID-19, est ... more

Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (‎CNBG)‎, Sinopharm (28 October 2021), updated 15 March 2022

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the back ... more

WHO position paper on hepatitis A vaccines – October 2022

Pan American Health Organization PAHO ; World Health Organization WHO (2022) C_WHO

The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professional ... more

Sudan Wash Sector - Strategic Operational Framework 2022

UNICEF (2022) C_UNICEF

This Strategic Operating Framework (SOF) has been developed to guide WASH Sector partners in responding to humanitarian needs in Sudan in conjunction with the existing and forthcoming humanitarian response plans (2022 and 2023). This SOF is drafted in consultation with the Strategic ... more

Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing

World Health Organization WHO (2022) C_WHO

These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary include ... more

Interim recommendations for use of the Novavax NVX-CoV2373 vaccine against COVID-19: interim guidance, 20 December 2021

World Health Organization WHO (2022) C_WHO

27 September 2022 These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the b ... more

Target product profile for a test for rhodesiense human African trypanosomiasis diagnosis usable in peripheral health facilities

World Health Organization World Health Organization WHO (2021) C_WHO

The development of this target product profile (TPP) was led by the WHO Department of Control of Ne- glected Tropical Diseases (NTD) following standard WHO guidance for TPP development. In order to identify and prioritize diagnostic needs, a WHO NTD Diagnostics Technical ... more

Use of high burden country lists for TB by WHO in the post-2015 era

World Health Organization (2015) C_WHO

Discussion paper initially prepared in April 2015 to facilitate feedback, and finalized after the June 2015 meeting of WHO’s Strategic and Technical Advisory Group for TB (STAG-TB).

Post-Traumatic Disorder: Treatment and Referral Guide

The South African Depression and Anxiety Group (2006) C2

How to recognise Post-Traumatic Stress Disorder | The nature and cause of Post-Traumatic Stress Disorder | Treatment and referral | Sources of further information | Compiled by the Scientific & Advisory Board Members of the South African Depression ... more

Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons

World Health Organization WHO (2021) C_WHO

Interim guidance, 26 October 2021 This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021. SAGE said moderately and severely immu ... more

Agenda for the Americas on Health, Environment, and Climate Change 2021–2030

Pan American Health Organization (2021) C_WHO

This publication presents the Agenda for the Americas on Health, Environment, and Climate Change 2021–2030 (the Agenda). The Agenda is a call to action to the health sector to lead the charge to address environmental determinants of health in the Americas. The Pan American Health Organization (PAH ... O) will work with Member States to achieve its goal and objective to ensure healthy lives and promote well-being for all at all ages using a sustainable and equitable approach that places a priority on reducing health inequity. The Agenda has been developed under the umbrella of the WHO Global Strategy on Health, Environment, and Climate Change, and builds upon the commitments set forth in the Sustainable Health Agenda for the Americas 2018–2030 and the PAHO Strategic Plan 2020–2025. The Agenda was developed in consultation with the Technical Advisory Group and through a consensus-driven decision-making process with Member States during the 2019–2020 period. Looking toward the achievement of Sustainable Development Goal 3, the Agenda focuses on: improving the performance of environmental public health programs and institutions; fostering environmentally resilient and sustainable health systems; and promoting environmentally healthy and resilient cities and communities. Its implementation will be context-specific, based on the needs and realities of the countries. It will benefit countries and territories by promoting good governance practices, strengthening the leadership and coordination roles of the health sector, fostering cross-sectoral action, focusing on primary prevention, and enhancing evidence and communication. It will facilitate access to human, technical, and financial resources necessary to address environmental determinants of health and ensure that the Region is fully engaged in global health, environment, and climate change processes and agreements. The objective of the Agenda is to strengthen the capacity of health actors in the health and non-health sectors to address and adapt to environmental determinants of health (EDHs), prioritizing populations living in conditions of vulnerability, in order to meet Outcome 18 of the PAHO Strategic Plan 2020–2025 directly and several other outcomes of the Plan indirectly. To address and adapt to the challenges of EDHs in the Region, an integrated and evidence-informed approach within the health sector and across sectors will be needed, one enabled, and supported by good governance practices, adequate management mechanisms, high-level political will, and adequate human, technical, technological, and financial resources. more

Documento de referência sobre a vacina AZD1222 contra COVID-19 desenvolvida pela Universidade de Oxford e pela AstraZeneca, 1 de março de 2021

Pan American Health Organisation PAHO (2021) C_WHO

Este documento de referência foi preparado pelo Grupo de Trabalho sobre Vacinas contra COVID-19 do Grupo Consultivo Estratégico de Especialistas em Imunização (SAGE) para orientar as discussões do SAGE em sua reunião extraordinária de 8 de fevereiro de 2021, que resultou na publicação do do ... more

National Comprehensive Covid19 Management Handbook First Edition 2020

Ministry of Health, Federal Democratic Republic of Ethiopia Ministry of Health, Federal Democratic Republic of Ethiopia (2020) C1

Cognizant of the need for standardization of the response for COVID-19, the Federal Ministry of Health prepared this national guideline in an effort to contain the epidemic before it overwhelms the health care facilities. This national guideline is expected to guide policy makers and h ... more

Scabies Key facts

World Health Organization World Health Organization WHO (2020) C_WHO

Human scabies is a parasitic infestation caused by Sarcoptes scabiei var hominis. The microscopic mite burrows into the skin and lays eggs, eventually triggering a host immune response that leads to intense itching and rash. Scabies infestation may be complicated by bacterial infection, leading to t ... more

Monkeypox: Current status in West and Central Africa

World Health Organization (WHO) (2018) C_WHO

Monkeypox is an emerging viral zoonosis with symptoms similar to those observed in smallpox patients, although less severe. Since the global eradication of smallpox in 1980, monkeypox has emerged as the most important orthopoxvirus in humans. The Advisory ... more